Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: A two-year follow-up study

Artificial Organs

Volumn 31, Issue 12, 2007, Pages 892-895

  Vlahakos, Demetrios V ^a,c   Retsa, Kalliopi ^b   Kalogeropoulou, Sofia ^a   Katsoudas, Spiros ^a   Bacharaki, Dimitra ^a   Agroyannis, Basil ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Hyperparathyroidism; Metabolic acidosis; Renal failure

Indexed keywords

CALCIUM; CHLORINE COMPOUNDS; HEMODIALYZERS; METABOLISM; PATIENT MONITORING; PATIENT TREATMENT; SALTS;

ACID BASE; ARTERIAL BLOOD; BLOOD GAS; CHRONIC ACID; FOLLOW-UP STUDIES; HEMODIALYSIS PATIENT; HYPERPARATHYROIDISM; KIDNEY DISEASE; METABOLIC ACIDOSIS; RENAL FAILURE;

DIALYSIS;

CALCIUM; PHOSPHORUS; SEVELAMER;

ACID BASE BALANCE; ADULT; AGED; ARTERIAL GAS; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG MECHANISM; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERPARATHYROIDISM; KIDNEY DISEASE; LIPID METABOLISM; MALE; METABOLIC ACIDOSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SIDE EFFECT;

EID: 36448965235     PISSN: 0160564X     EISSN: 15251594     Source Type: Journal    
DOI: 10.1111/j.1525-1594.2007.00484.x     Document Type: Article

References (12)

1. Galassi A, Spiegel DM, Bellasi A, Block GA, Raggi P. Accelerated vascular calcification and relative hypoparathyroidism in incident haemodialysis diabetic patients receiving calcium binders. Nephrol Dial Transplant 2006 21 : 3215 22.
2. Chertow GM, Burke SK, Lazarus JM, et al. Poly[allylamine hydrochloride](Renagel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997 29 : 66 71.
3. Braun J, Asmus HG, Holzer H, Brunkhorst R, et al. Long-term comparison of a calcium-free phosphate binder and calcium carbonate-phosphorus metabolism and cardiovascular calcification. Clin Nephrol 2004 62 : 104 15.
4. Chertow GW, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium phosphate product and lipid profile on haemodialysis patients. Nephrol Dial Transplant 1999 14 : 2907 14.
5. Brezina B, Qunibi WY, Nolan CR. Acid loading during treatment with sevelamer hydrochloride: mechanisms and clinical implications. Kidney Int 2004 66 (Suppl. 90 S39-S45.
6. Marco MP, Muray S, Betriu A, Craver L, Belart M, Fernandez E. Treatment with sevelamer decreases bicarbonate levels in hemodialysis patients. Nephron 2002 92 : 499 500.
7. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphosphatemia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004 65 : 1914 26.
8. Sadek T, Mazouz H, Bahloul H, Oprisiu R, et al. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Nephrol Dial Transplant 2003 18 : 582 8.
9. De Santo NG, Frangiosa A, Anastasio P, Marino A, et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006 19 (Suppl. 9 S108-14.
10. Agroyannis B, Fourtounas C, Tzanatos H, Dalamangas A, Vlahakos DV. Relationship between interdialytic weight gain and acid-base status in hemodialysis by bicarbonate. Artif Organs 2002 26 : 385 7.
11. Brewster UC, Ciampi MA, Abu-Alfa AK, Reilly RF. Long-term comparisons of sevelamer hydrochloride to calcium-containing phosphate binders. Nephrology 2006 11 : 142 6.
12. Sonikian MA, Pani IT, Iliopoulos AN, Koutala KG, Marioli SI, Vlassopoulos DA. Metabolic acidosis aggravation and hyperkalemia in hemodialysis patients treated by sevelamer hydrochloride. Ren Fail 2005 27 : 143 7.